Skip to main content
. 2017 Jun 6;7:2877. doi: 10.1038/s41598-017-03296-6

Table 3.

Diagnostic performances of the SUV parameters at 18F-Alfatide PET/CT in patients with NSCLC.

NSCLC Sensitivity Specificity PPV NPV Accuracy
% 95%CI % 95%CI % 95%CI % 95%CI % 95%CI
Visual 100.0 83.2–100 94.9 90.5–97.6 69.0 49.2–84.7 100 97.8–100 95.4 91.5–97.9
SUVmax 90.0 68.3–98.2 96.0 92.0–98.4 72.0 50.6–87.93 98.8 95.4–99.9 95.4 91.5–97.9
SUVmean 85.0 62.1–96.8 92.1 87.0–95.6 54.8 36.0–72.7 98.2 94.8–99.62 91.3 86.5–94.9
SUVLN/PT 85.0 62.1–96.8 81.2 75.3–87.2 34.7 21.7–49.6 98.0 94.2–99.6 82.1 76.1–87.2
SUVLN/MBP 85.0 62.1–96.8 96.0 92.0–98.4 70.8 48.9–87.4 98.3 95.0–99.6 94.9 90.8–97.5
SUVLN/M 100.0 83.2–100 89.2 83.7–93.4 51.3 34.8–67.6 100 97.7–100 90.3 85.3–94.1

NSCLC, non-small cell lung cancer; LN, lymph node; MBPS, mediastinal blood pool; M, muscle; PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval; SUV, standardized uptake value.